Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EXL 01

Next Previous
X
Search
Drug Profile

EXL 01

Alternative Names: EXL-01

Latest Information Update: 12 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Exeliom Biosciences
  • Class Anti-inflammatories; Antibacterials; Antineoplastics; Bacteria
  • Mechanism of Action Bacteria replacements; Gastrointestinal microbiome modulators; Interleukin 10 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Clostridium difficile infections
  • Phase I Crohn's disease
  • Preclinical Gastric cancer; Liver cancer; Non-small cell lung cancer; Ulcerative colitis

Most Recent Events

  • 07 Jun 2024 Exeliom Biosciences plans a phase I/II trial for Non small cell lung cancer (Inoperable/Unresectable, Metastatic disease, Late-stage disease, Second-line therapy or greater, Combination therapy) (PO) in September 2024 (NCT06448572)
  • 07 May 2024 Phase-I/II clinical trials in Clostridium difficile infections in France (PO) (NCT06306014) (EudraCT2023-506232-32-00)
  • 05 Mar 2024 Hospices Civils de Lyon in collaboration with Exeliom Biosciences plans a phase I/II trial in Clostridium difficile infections in France (PO, capsule) in April 2024 (NCT06306014)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top